FDA Approves Omadacycline for CABP and ABSSSI

This new-generation tetracycline carries less risk for bacterial drug resistance than older tetracyclines and fewer adverse effects than quinolones.

On October 2, 2018, the U.S. FDA approved omadacycline (Nuzyra) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).

Omadacycline is a new-generation tetracycline, dosed once daily in both oral and intravenous forms, that was designed to subvert common tetracycline resistance mechanisms, including efflux and ribosomal protection. Among gram-positive bacteria, it exhibits excellent in vitro activity against methicillin-susceptible and methicillin-resistant Staphylococcus aureus (MIC₉₀, 0.5 mg/L), vancomycin-susceptible and vancomycin-resistant enterococci (MIC₉₀, 0.5 mg/L), penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae (MIC₉₀, 0.12 mg/L),…

Author

George Sakoulas, MD

Disclosures

Consultant/Advisory BoardParatek Pharmaceuticals; Nestle Corp.; AbbVie; Shionogi

Speaker’s BureauAllergan/AbbVie; Paratek Pharmaceuticals; Nestle Corp.

RoyaltiesUpToDate

Editorial BoardsAntimicrobial Agents and Chemotherapy; Open Forum Infectious Diseases